VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,260,419 | +3.8% | 142,417 | +1.7% | 0.87% | -21.6% |
| Q2 2023 | $6,991,600 | -17.1% | 140,000 | -37.8% | 1.11% | -41.8% |
| Q1 2023 | $8,433,000 | -29.7% | 225,000 | -10.0% | 1.91% | -33.9% |
| Q4 2022 | $11,987,501 | +143.7% | 250,000 | +10.6% | 2.89% | +222.4% |
| Q2 2022 | $4,918,000 | -35.5% | 225,991 | -28.5% | 0.90% | -10.6% |
| Q1 2022 | $7,630,000 | +8.7% | 315,991 | +7.1% | 1.00% | -4.1% |
| Q4 2021 | $7,021,000 | -6.2% | 295,111 | 0.0% | 1.05% | +98.5% |
| Q3 2021 | $7,486,000 | -25.8% | 295,111 | -34.1% | 0.53% | -35.3% |
| Q2 2021 | $10,087,000 | +1.9% | 448,110 | -10.6% | 0.82% | +144.7% |
| Q1 2021 | $9,897,000 | +34.9% | 501,110 | +81.5% | 0.33% | +3.1% |
| Q4 2020 | $7,336,000 | +821.6% | 276,110 | +1613.9% | 0.32% | +456.9% |
| Q3 2020 | $796,000 | -82.0% | 16,110 | -88.5% | 0.06% | -83.5% |
| Q2 2020 | $4,419,000 | – | 139,813 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |